Physician profile
Amit Dhingra
NPI 1437122397
$10,975.73
in general payments reported to CMS, 2019-2025
47 companies · $1,094 in 2025
The $1,094 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,808 · 2020: $1,673 · 2021: $1,897 · 2022: $1,757 · 2023: $1,320 · 2024: $1,428 · 2025: $1,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,819 · Education: $22.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,818.82 |
| Education | $22.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,504.78 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| United Therapeutics Corporation | $1,115.78 | 2019-2025 | Tyvaso, Tyvaso, Orenitram |
| Astrazeneca Pharmaceuticals Lp | $980.66 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $977.22 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Actelion Pharmaceuticals US, INC. | $871.62 | 2019-2024 | Opsumit, Uptravi |
| Genzyme Corporation | $712.94 | 2019-2025 | |
| Csl Behring | $481.71 | 2019-2024 | Hizentra |
| Regeneron Healthcare Solutions, INC. | $458.93 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $394.73 | 2019-2024 | Xolair |
| Grifols USA, LLC | $336.58 | 2022-2025 | Xembify |
| Baxter Healthcare | $331.36 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Advanced Respiratory, INC | $302.09 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $255.13 | 2020-2023 | Glassia |
| Mylan Specialty L.P. | $180.78 | 2019-2024 | Yupelri |
| Electromed, INC. | $173.70 | 2021-2025 | Smartvest |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $168.52 | 2019-2021 | |
| Octapharma USA, INC. | $141.07 | 2021 | |
| Merck Sharp & Dohme LLC | $134.31 | 2019-2025 | Zerbaxa |
| Optinose US, INC. | $124.20 | 2019-2022 | |
| Inspire Medical Systems, INC. | $110.93 | 2023-2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $96.50 | 2022 | |
| Sunovion Pharmaceuticals INC. | $92.97 | 2019-2021 | |
| Insmed, INC. | $86.13 | 2019-2025 | Arikayce |
| Pulmonx Corporation | $83.14 | 2021-2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Boston Scientific Corporation | $79.30 | 2019-2024 | |
| Abbott Laboratories | $77.12 | 2019-2024 | Proclaim |
| Inogen, INC. | $73.26 | 2022-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Shire North American Group INC | $65.55 | 2019 | |
| Amgen INC. | $61.08 | 2022-2025 | Tezspire |
| Philips North America LLC | $60.07 | 2019-2021 | |
| Gilead Sciences, INC. | $59.26 | 2019 | |
| Verona Pharma, INC. | $56.55 | 2025 | Ohtuvayre |
| Pharming Healthcare, INC. | $49.04 | 2025 | Ruconest |
| Teva Pharmaceuticals USA, INC. | $41.04 | 2019-2020 | |
| Viatris Specialty LLC | $25.40 | 2025 | Yupelri |
| Zoll Respicardia, INC. | $23.52 | 2024 | Remede System |
| Circassia INC. | $22.31 | 2019 | |
| Springworks Therapeutics, INC. | $22.12 | 2025 | Gomekli |
| Veran Medical Technologies, INC. | $19.89 | 2020 | |
| Blueprint Medicines Corporation | $19.73 | 2023 | Ayvakit |
| Phadia US INC. | $18.12 | 2022 | |
| Mallinckrodt Hospital Products INC. | $17.37 | 2022 | |
| Allergan, INC. | $16.03 | 2019 | |
| Amarin Pharma, INC. | $14.60 | 2020 | |
| Medtronic USA, INC. | $13.76 | 2019 | |
| Pfizer INC. | $13.44 | 2022 | |
| 3b Medical, INC. | $11.39 | 2025 | Luna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Dhingra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.